New guidance on preventing cardiovascular (CV) and renal complications in type 2 diabetes (T2D) emphasizes tailoring therapy to a patient’s individual risk profile.

The living guidelines , published as part of the BMJ ’s “Rapid Recommendations” initiative, include a strong recommendation for SGLT2 inhibitors and GLP-1 receptor agonists (RAs) in patients at high risk for CV or kidney complications but recommend against their routine use in lower-risk patients with a preference for treatments based on each individual’s specific needs.

“These risk-stratified recommendations provide personalized medicine and represent the first international living guidelines on this topic, meaning they will be dynamically updated and therefore continue to be relevant for all doctors in the world,” senio

See Full Page